Aarti Drugs 

₹518.6
52
-₹6.7-1.28% Thursday 10:00

İstatistikler

Günlük Yüksek
-
Günlük Düşük
-
52H Yüksek
-
52H Düşük
-
Hacim
-
Ort. Hacim
-
Piyasa Değeri
48.7B
F/K Oranı
28.82
Temettü Verimi
0.19%
Temettü
1

Yaklaşan

Temettüler

0.19%Temettü Verimi
10Y Büyüme
-12.38%
5Y Büyüme
31.95%
3Y Büyüme
N/A
1Y Büyüme
N/A

Kazançlar

23OctBeklenen
Q1 2023
Q2 2023
Q3 2023
Q4 2023
Q1 2024
Q2 2024
Sonraki
3.61
3.91
4.21
4.5
Beklenen EPS
N/A
Gerçek EPS
N/A

İnsanlar Ayrıca Takip Eder

Bu liste, AARTIDRUGS.NSE adlı kişiyi Stock Events'te takip eden kişilerin izleme listelerine dayanmaktadır. Yatırım tavsiyesi değildir.

Rakipler

Bu liste, son piyasa olaylarına dayalı bir analizdir. Bir yatırım önerisi değildir.

Hakkında

Aarti Drugs Limited, through its subsidiaries, manufactures and markets active pharmaceutical ingredients (APIs), pharmaceutical intermediates, specialty chemicals, and formulations in India and internationally. The company offers aceclofenac, celecoxib, diclofenac sodium, diclodenac potassium, diclofenac diethylamine, diclofenac resinate, diclofenac epolamine, nimesulide, ciprofloxacin HCL, enrofloxacin base, gatifloxacin sesquihydrate, levofloxacin base, moxifloxacin, norfloxacin, ofloxacin, metronidazole benzoate, ornidazole, secnidazole, tinidazole, clopidogrel bisulphate, ticlopidine HCL, metformin HCL, pioglitazone HCL, teneligliptin, vildagliptin, fluconazole, ketoconazole, tolnaftate, zolpidem tartrate, niacin, raloxifene HCL, and acamprosate. It also provides benzene sulphonyl chloride, benzene sulphonic acid, benzene sulphonic acid methyl ester, sodium benzene sulfinate, para toluene sulphonyl chloride, methyl para toluenesulfonate, sodium para toluenesulfinate, para chlorobenzenesulfonyl chloride, formamide, calcium fluoride, potasium formate, benzenesulfonamide, ethyl p- toluenesulfonate, N,N',N'-tris-(4-toluene sulfonyl)-diethylenetriamine, ortho para toluene sulfonamides, ortho para toluene sulfonamides acid methyl ester, para chlorobenznesulfonamide, para toluenesulfonyl hydrazide, para toluenesulfonamide, and sodium benzenesulfonate. In addition, it offers pharma intermediate products, which includes Celecoxib, Ciprofloxacin, Clopidogrel, Diclofenac, Ketoconazole, Nimesulide, Raloxifene, Tinidazole, and Zolpidem. Further, the company develops drugs for the antioxidant, antifungal, cardiovascular, and antidiabetic therapeutic areas. The company was incorporated in 1984 and is headquartered in Mumbai, India.
Show more...
CEO
Mr. Prakash Moreshwar Patil
Çalışanlar
1064
Ülke
IN
ISIN
INE767A01016

Listeler